North Carolina' s Parion Sciences and Gilead have initiated a Phase I clinical trial of GS9411, and experimental therapy designed to increase airway hydration for the treatment of pulmonary disease. Parion will get a $5 million milestone payment from Gilead. Release [1]
Links:
[1] http://www.fiercebiotech.com/press-releases/parion-sciences-announces-initiation-phase-i-clinical-trial-evaluate-safety-and-tol-0